Cytomegalovirus disease and infection in lung transplant recipients in the setting of planned indefinite valganciclovir prophylaxis.
about
CMV: Prevention, Diagnosis and TherapyVoriconazole Exposure and Risk of Cutaneous Squamous Cell Carcinoma, Aspergillus Colonization, Invasive Aspergillosis and Death in Lung Transplant Recipients.Molecular and Culture-Based Bronchoalveolar Lavage Fluid Testing for the Diagnosis of Cytomegalovirus PneumonitisCytomegalovirus infections in solid organ transplantation: a review.Lung transplantation: a treatment option in end-stage lung disease.Emerging cytomegalovirus management strategies after solid organ transplantation: challenges and opportunities.Cytomegalovirus disease is associated with higher all-cause mortality after lung transplantation despite extended antiviral prophylaxis.Risk factors, survival, and impact of prophylaxis length in cytomegalovirus-seropositive lung transplant recipients: A prospective, observational, multicenter study.Everolimus Versus Mycophenolate Mofetil De Novo After Lung Transplantation: A Prospective, Randomized, Open-Label Trial.
P2860
Q26824869-0E23C197-F284-4899-8777-B8E45C3A06D7Q36480011-D29764AD-5F0B-4991-99FD-034A53DBA89EQ36575610-CF0F7AF4-DDA0-4AD4-B27C-D9FBFCFA098FQ37359332-8E7B2ECF-FD41-4595-8FAD-8CC8D94C6E1BQ37642300-9D5B7D8C-9717-4F7F-AB96-927F12F755CAQ38225475-71EF63C5-A15B-4F86-943D-2B2ADA977567Q38678532-F819290F-5E49-421B-93BB-80F651E27850Q40293836-9ABA0105-ADE7-4B0A-A4D6-DBBFB883324BQ40484098-191BC80A-CB64-4EB5-A981-D5199E3F15B3
P2860
Cytomegalovirus disease and infection in lung transplant recipients in the setting of planned indefinite valganciclovir prophylaxis.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Cytomegalovirus disease and in ...... te valganciclovir prophylaxis.
@en
Cytomegalovirus disease and in ...... te valganciclovir prophylaxis.
@nl
type
label
Cytomegalovirus disease and in ...... te valganciclovir prophylaxis.
@en
Cytomegalovirus disease and in ...... te valganciclovir prophylaxis.
@nl
prefLabel
Cytomegalovirus disease and in ...... te valganciclovir prophylaxis.
@en
Cytomegalovirus disease and in ...... te valganciclovir prophylaxis.
@nl
P2093
P2860
P1476
Cytomegalovirus disease and in ...... te valganciclovir prophylaxis.
@en
P2093
J A Golden
J P Singer
N Roubinian
P V Chin-Hong
P2860
P304
P356
10.1111/J.1399-3062.2012.00723.X
P577
2012-03-05T00:00:00Z